|
|
| Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help |
|
Health Affairs, 25, no. 5 (2006):
1309-1317
doi: 10.1377/hlthaff.25.5.1309 © 2006 by Project HOPE |
|
 |
|||||||||||||
| ||||||||||||||||||||
How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation
Reed
et al.
Health Affairs
25, no. 5 (2006): 1309
Online Technical Appendix
This Data Supplement consists of supplemental material that, because of space constraints, was not included with the published paper by Shelby D. Reed, Robert M. Califf, and Kevin A. Schulman, "How Changes in Drug-Safety Regulations Affect the Way Drug and Biotech Companies Invest in Innovation."
DISCLAIMER: This material is presented to supplement the published paper. Although it was part of the manuscript that was subjected to the scrutiny of external reviewers, it has not been edited or formatted by the editors of Health Affairs; the authors are solely responsible for any errors herein.
Files in this Data Supplement:
| Home | | | Current Issue | | | Archives | | | Topic Collections | | | Search | | | Blog | | | Subscribe | | | Contact Us | | | Help |
|
© 2001-2009 Project
HOPE–The People-to-People Organization |
||||||||||||||||